



## Adam Sperling, MD, PhD

Assistant Professor of Medicine (Hematology)

### Bio

---

#### BIO

Dr. Sperling received his medical degree and PhD in Biological Chemistry from the University of California, Los Angeles in 2011. He completed his residency in internal medicine at the Brigham and Women's Hospital and his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He received board certification from the American Board of Internal Medicine in 2014, in Medical Oncology in 2017 and in Hematology in 2018. He was a member of the staff at the Dana-Farber Cancer Institute and the Brigham and Women's Hospital in Boston from 2018-2026, where he was an Assistant Professor of Medicine at Harvard Medical School. He joined the faculty at Stanford University in 2026, where he is a hematologist and basic and translational researcher in hematologic malignancies. He cares for patients with multiple myeloma and related blood cancers and his research focuses on understanding the mechanisms of disease evolution from pre-malignant conditions and the development of drug resistance in multiple myeloma and other hematologic malignancies.

#### ACADEMIC APPOINTMENTS

- Assistant Professor, Medicine

### Publications

---

#### PUBLICATIONS

- **Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.** *Molecular cell*  
Słabicki, M., Park, J., Nowak, R. P., Roy Burman, S. S., Pellman, J., Zou, C., Razumkov, H., Carreiro, J., Rastogi, S., Goldstein, A., Nagiec, M. M., Donovan, K. A., Che, et al  
2025; 85 (16): 3184-3201.e14
- **Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium.** *Blood cancer discovery*  
Razzo, B. M., Midha, S., Portuguese, A. J., Grajales-Cruz, A. F., De Menezes Silva Corraes, A., Costello, P., Liu, Y., Sperling, A. S., Nadeem, O., Dima, D., Banerjee, R., Cowan, A. J., Afrough, et al  
2025
- **Development of PDE6D and CK1alpha Degraders through Chemical Derivatization of FPFT-2216.** *Journal of medicinal chemistry*  
Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y., Sperling, A. S., Zhang, T., Ebert, B. L., Fischer, E. S., Gray, N. S.  
1800
- **Association of Clonal Hematopoiesis with Chronic Obstructive Pulmonary Disease.** *Blood*  
Miller, P., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., Miller, B., Shi, W., Viswanathan, et al  
2021
- **Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.** *American journal of hematology*

Garcia, J. S., Bhatt, S., Fell, G., Sperling, A. S., Burgess, M., Keshishian, H., Yilma, B., Brunner, A., Neuberg, D., Carr, S. A., Ebert, B. L., Ballen, K., Stone, et al  
2019

- **The Drosophila BRM complex facilitates global transcription by RNA polymerase II** *EMBO JOURNAL*  
Armstrong, J. A., Papoulas, O., Daubresse, G., Sperling, A. S., Lis, J. T., Scott, M. P., Tamkun, J. W.  
2002; 21 (19): 5245-5254